Compare Novavax Inc (NVAX) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Union Pacific Corporation — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Union Pacific Corporation trades at $278.62 (market cap $165.27B). The key difference: Union Pacific Corporation is far larger — about 90.8× Novavax Inc's market cap, and Union Pacific Corporation pays a 2.04% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Union Pacific Corporation for 105 Days on average.
| NVAX | UNP | |
|---|---|---|
Market Cap | $1.82B | $165.27B |
Volume | 6,198,505 | 1,474,117 |
Sector | Health | Industrials |
52-Week High | $12.56 | $310.62 |
52-Week Low | $6.22 | $216.37 |
Typical Hold Time | 59 Days | 105 Days |
Enterprise Value | $1.39B | $194.33B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Union Pacific (UNP) trades at $278.34, up 1.33% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 28.85% net margins and consistent earnings beats, while maintaining positive cash flow generation. Recent developments include deployment of battery-electric locomotives and progress on the Norfolk Southern combination, positioning the railroad for future growth.
The outlook remains positive with analyst consensus pointing to 19% upside potential to the $332.10 price target. Key opportunities include pricing power from high diesel costs shifting freight to rail, while risks center on merger uncertainty and fuel cost pressures on operating ratios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
